R
Robert Z. Orlowski
Researcher at University of Texas MD Anderson Cancer Center
Publications - 605
Citations - 40776
Robert Z. Orlowski is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 83, co-authored 543 publications receiving 34699 citations. Previous affiliations of Robert Z. Orlowski include University of Texas Health Science Center at Houston & Duke University.
Papers
More filters
Journal ArticleDOI
P-233: Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma
Melody R. Becnel,Christopher J. Ferreri,Lei Feng,Tiffany Richards,Sandra B. Horowitz,Nimisha Patel,Dan S. Gombos,Azadeh Razmandi,A. Murga,Sherif Seif,George Youssef,Kevin Murphy,Gregory P. Kaufman,Donna M. Weber,Krina K. Patel,Sheeba K. Thomas,Elisabet E. Manasanch,Robert Z. Orlowski,Hans C. Lee +18 more
Journal ArticleDOI
P965: follow-up analysis of the randomized phase ii trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (swog-1211)
S. Usmani,Antje Hoering,Sikander Ailawadhi,Rachael Sexton,Brea Lipe,Jason Valent,Michael Rosenzweig,Jeffrey A. Zonder,Madhav V. Dhodapkar,Natalie S. Callander,Tom Zimmerman,P. Voorhees,B. Durie,S. Vincent Rajkumar,P Richardson,Robert Z. Orlowski +15 more
TL;DR: Survition outcomes on the first randomized trial in newly diagnosed HRMM, S1211, to follow-up on the previously reported progression-free survival (PFS) are provided.
Phase I T rial o f t he P roteasome I nhibitor P S-341 i n P atients With R efractory H ematologic M alignancies
Robert Z. Orlowski,Thomas E. Stinchcombe,Beverly S. Mitchell,Thomas C. Shea,Albert S. Baldwin,Stephanie Stahl,Julian Adams,Dixie-Lee Esseltine,Peter J. Elliott,Christine S. Pien,Roberto Guerciolini,Jessica K. Anderson,Natalie D. Depcik-Smith,Rita Bhagat,Mary Jo Lehman,Steven C. Novick,Steven L. Soignet +16 more
TL;DR: PS-341 showed activity against refractory multiple myeloma and possibly non-Hodgkin’s lymphoma in this study, and merits further investigation in these populations.
Challenges in the management of high-risk multiple myeloma
Faith E. Davies,Charlotte Pawlyn,Saad Z. Usmani,Jesús F. San Miguel,Hermann Einsele,Eileen M Boyle,Jill Corre,Daniel Auclair,Hearn Jay Cho,Sagar Lonial,Pieter Sonneveld,A. Keith Stewart,P. Leif Bergsagel,M. L. Kaiser,Katja Weisel,Jonathan J Keats,Joseph R. Mikhael,Kathryn E. Morgan,Irene M. Ghobrial,Robert Z. Orlowski,C. Ola Landgren,Francesca Gay,Jo Caers,Wee Joo Chng,Ajai Chari,Brian A Walker,Shaji Kumar,Luciano J. Costa,Kenneth C. Anderson,Gareth J. Morgan +29 more
TL;DR: In this article , the authors discuss the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma, and propose a more personalized approach to therapy.
Journal ArticleDOI
P-260: Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
Maria-Victoria Mateos,Paul G. Richardson,Katja Weisel,Philippe Moreau,Jesús F. San Miguel,Hartmut Goldschmidt,Robert Z. Orlowski,Pieter Sonneveld,Donna E. Reece,Kenshi Suzuki,Nizar J. Bahlis,Sung-Soo Yoon,Andrew Spencer,Ajay K. Nooka,Vania Hungria,Torben Plesner,Dina Ben Yehuda,Huiling Pei,Wendy Garvin Mayo,Xueliang Gai,Jodi L Carey,Robin Carson,Meletios A. Dimopoulos +22 more